Table 4a.
Clinical outcomes among all patients according to PPI use before and after PSM
| Clinical endpoint | Before PSM | After PSM | ||||||
|---|---|---|---|---|---|---|---|---|
| PPI (n = 2142) | No PPI (n = 5726) | χ2 | P | PPI (n = 1966) | No PPI (n = 1966) | χ2 | P | |
| Primary endpoint | ||||||||
| MACCE | 273 (12.7) | 716 (12.5) | 0.086 | 0.769 | 244 (12.4) | 249 (12.7) | 0.048 | 0.827 |
| Secondary endpoint | ||||||||
| All cause death | 30 (1.4) | 75 (1.3) | 0.097 | 0.755 | 25 (1.3) | 27 (1.4) | 0.080 | 0.777 |
| MI | 51 (2.4) | 116 (2.0) | 0.950 | 0.330 | 48 (2.4) | 48 (2.4) | <0.001 | 0.998 |
| Unplanned TVR | 195 (9.1) | 504 (8.8) | 0.199 | 0.655 | 174 (8.9) | 176 (9.0) | 0.006 | 0.937 |
| Stent thrombosis | 25 (1.2) | 52 (0.9) | 1.095 | 0.295 | 21 (1.1) | 17 (0.9) | 0.425 | 0.515 |
| Stroke | 31 (1.4) | 78 (1.4) | 0.084 | 0.772 | 28 (1.4) | 22 (1.1) | 0.721 | 0.396 |
| Safety endpoint | ||||||||
| Bleeding | 142 (6.6) | 372 (6.5) | 0.060 | 0.806 | 137 (7.0) | 116 (5.9) | 1.860 | 0.173 |
| BARC 3 or 5 | 10 (0.5) | 10 (0.5) | 0.095 | 0.758 | 10 (0.5) | 4 (0.2) | 2.623 | 0.105 |
| GI bleeding | 36 (1.7) | 71 (1.2) | 2.272 | 0.132 | 36 (1.8) | 23 (1.2) | 2.960 | 0.085 |
Data are presented as n (%). PPI: Proton-pump inhibitors; PSM: Propensity score matching; MACCE: Major adverse cardiovascular and cerebrovascular events; MI: Myocardial infarction; TVR: Target vessel revascularization; BARC: Bleeding Academic Research Consortium; GI: Gastrointestinal.